Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 9/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4853230 | 1.00 | SIGMAR1 (0.42) | SIGMAR1TMEM97PTGDR2PKMNPSR1 | |
| SCHEMBL2488624 | 0.80 | PARP1 (0.46) | SIGMAR1TMEM97PTGDR2PKM | |
| SCHEMBL4859941 | 0.80 | PARP1 (0.46) | SIGMAR1TMEM97PTGDR2PKM | |
| SCHEMBL14248396 | 0.77 | HTR2C (0.50) | NPSR1 | |
| SCHEMBL3158902 | 0.75 | SIGMAR1 (0.48) | SIGMAR1TMEM97 | |
| SCHEMBL3158897 | 0.75 | SIGMAR1 (0.48) | SIGMAR1TMEM97 | |
| SCHEMBL3161043 | 0.75 | SIGMAR1 (0.48) | SIGMAR1TMEM97 | |
| SCHEMBL3161029 | 0.75 | SIGMAR1 (0.48) | SIGMAR1TMEM97 | |
| SCHEMBL3158912 | 0.75 | SIGMAR1 (0.48) | SIGMAR1TMEM97 | |
| SCHEMBL3157643 | 0.75 | TACR1 (0.47) | SIGMAR1TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513814-B1 | NOVEL PIPERIDINE COMPOUND | MITSUBISHI TANABE PHARMA CORP (JP) | 2010-03-17 | — | — | EP | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7619092-B2 | Piperidine compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-17 | — | — | US | disclosed |
| US-7390905-B2 | Piperidine compound and process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-06-24 | — | — | US | disclosed |
| US-20070112029-A1 | Piperidine compound and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1513814-A4 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO (JP) | 2007-03-14 | — | — | EP | disclosed |
| EP-1693367-A1 | PIPERIDINE COMPOUND AND METHOD FOR PRODUCING SAME | TANABE SEIYAKU CO., LTD. (JP) | 2006-08-23 | — | — | EP | disclosed |
| US-20050239829-A1 | Novel piperidine compound | TANABE SEIYAKU CO. LTD. (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1513814-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099787-A1 | NOVEL PIPERIDINE COMPOUND | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239829-A1 | Novel piperidine compound | EP300, BRD1, CBR3 | SIGMAR1 14/4885TMEM97 654/4885PTGDR2 677/4885 |
| US-20070112029-A1 | Piperidine compound and process for preparing the same | NPSR1, TACR1, PRLHR | SIGMAR1 52/4885TMEM97 349/4885PTGDR2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.